Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus

Atsumi, Satoru; Matsumine, Akihiko; Toyoda, Hidemi; Niimi, Rui; Iino, Takahiro; Nakamura, Tomoki; Matsubara, Takehiro; Asanuma, Kunihiro; Komada, Yoshihiro; Uchida, Atsushi; Sudo, Akihiro

doi:10.3892/ijo.2012.1514

Cited by 19 publications

(18 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have also shown that live-attenuated poliovirus induces apoptotic cell death in tumors, including gliomas (28) and neuroblastomas (29), through the interaction with CD155 in vitro and in vivo . We previously showed that live-attenuated poliovirus has the potential to treat soft tissue sarcomas expressing CD155 as a form of oncolytic virotherapy (26). We therefore suggest that soft tissue sarcomas with upregulated CD155 expression may be candidates for oncolytic virotherapy using live-attenuated poliovirus.…”

Section: Discussionmentioning

confidence: 99%

“…We have previously shown that CD155 was widely expressed in various human bone and soft tissue sarcoma cell lines (26), but there have so far been no studies describing the clinicopathological implications of CD155 in soft tissue sarcomas. The present study investigated whether the CD155 gene expression level in surgically resected human primary soft tissue sarcoma tissues has prognostic significance.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of CD155 mRNA expression in soft tissue sarcomas

et al. 2013

Self Cite

View full text Add to dashboard Cite

CD155 was initially identified as a receptor for poliovirus. Several studies have demonstrated that CD155 overexpression in cancer cells is significant in their migration, invasion, proliferation and metastasis. The objective of the present study was to investigate the correlation between CD155 expression and the clinical aggressiveness of soft tissue tumors. The CD155 expression levels in 43 surgically-resected soft tissue tumors were evaluated using the quantitative real-time polymerase chain reaction (PCR). The clinicopathogical factors affecting the expression levels of CD155 mRNA were investigated and the association between the expression levels of CD155 and patient prognosis was identified. The CD155 expression level was not correlated with the patient gender, site of the primary tumor, tumor depth, tumor size or presence of distant metastasis at presentation, but was correlated with patient age (Fisher’s exact test). The local recurrence-free survival rate for patients with a high CD155 expression level was observed to be significantly poorer compared with that of patients with low CD155 expression levels (P=0.0401). Moreover, a multivariate analysis indicated that a high CD155 expression level was an independent adverse prognostic factor for local recurrence-free survival (hazard ratio, 6.369; P=0.0328). The present study therefore suggests that the expression level of CD155 is a useful marker for predicting the local recurrence of soft tissue tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic significance of CD155 mRNA expression in soft tissue sarcomas

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…CD155 was initially identified as a receptor based on its ability to mediate the binding of poliovirus to host cells (7,8), and also known as a member of the immunoglobulin family of cell adhesion molecules (9,10). CD155 is broadly distributed at low levels on epithelial and endothelial cells in many tissues (11), but overexpressed in various carcinomas including soft tissue sarcoma (12,13), colorectal cancer (14), lung adenocarcinoma (15), melanoma (16), neuroblastoma and glioblastoma (17,18). CD155 was subsequently shown to promote GBM cell migration and focal adhesion disassembly (19,20).…”

Section: Introductionmentioning

confidence: 99%

Overexpression of CD155 relates to metastasis and invasion in osteosarcoma

Zhuo

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

The rapid development of metastatic lesions remains the leading cause of mortality for patients with osteosarcoma. CD155 serves a key role in cancer cell migration, invasion and metastasis. However, the function and mechanism of CD155 has not been explored in osteosarcoma metastasis. In the present study, we found that CD155 was significantly upregulated in lung metastatic tissue and the highly metastatic cell line K7M2-WT (K7M2) of osteosarcoma. Overexpression of CD155 in K7M2 cells enhanced lung metastasis, while inhibition of CD155 by an anti-CD155 monoclonal antibody reduced metastasis. Blocking of CD155 also decreased migration and invasion of K7M2 cells . A western blot analysis revealed that blocking of CD155 inhibits metastasis by downregulating focal adhesion kinase (FAK) and phosphorylated FAK (pFAK) in osteosarcoma. The results revealed that CD155 serves a crucial role in the metastasis of osteosarcoma by regulating FAK and may provide a novel molecular target for therapeutic intervention in metastatic osteosarcoma.

show abstract

“…Collectively, these studies showed a safe yet profound anti-tumor response in JX-594 monotherapy and combination treatment groups in comparison to sorafenib alone. [79][80][81] Several strategies have been tested in reducing PV neurotoxicity: (1) use of live-attenuated poliovirus vaccines, 82 (2) delivery of engineered PV genome deficient of P1 coding region (replicons), thereby preventing the formation of new viral progenies and spread, 83 (3) A133G mutation in cis-acting replication element (CRE) and relocation of CRE to a spacer region, 84 (4) replacement of internal ribosome entry site (IRES) of PV (PVSRIPO) with that of human rhinovirus 2 (HRV2). 85 Ribonucleoprotein complex formed in PVSRIPO is incompatible with HRV2 IRES-mediated translation in normal human central nervous system, therefore, rendering the neuronal incompetence of PVSRIPO.…”

Section: Dovepressmentioning

confidence: 99%

<p>Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development</p>

Jayawardena¹,

Poirier²,

Burga³

et al. 2020

View full text Add to dashboard Cite

Oncolytic viruses (OVs) are replication competent agents that selectively target cancer cells. After penetrating the tumor cell, viruses replicate and eventually trigger cell lysis, releasing the new viral progeny, which at their turn will attack and kill neighbouring cells. The ability of OVs to self-amplify within the tumor while sparing normal cells can provide several advantages including the capacity to encode and locally produce therapeutic protein payloads, and to prime the host immune system. OVs targeting of cancer cells is mediated by host factors that are differentially expressed between normal tissue and tumors, including viral receptors and internalization factors. In this review article, we will discuss the evolution of oncolytic viruses that have reached the stage of clinical trials, their mechanisms of oncolysis, cellular receptors, strategies for targeting cancers, viral neutralization and developments to bypass virus neutralization.

show abstract

Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus

Cited by 19 publications

References 46 publications

Prognostic significance of CD155 mRNA expression in soft tissue sarcomas

Prognostic significance of CD155 mRNA expression in soft tissue sarcomas

Overexpression of CD155 relates to metastasis and invasion in osteosarcoma

<p>Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development</p>

Contact Info

Product

Resources

About